Restoration of microRNA‑218 increases cellular chemosensitivity to cervical cancer by inhibiting cell‑cycle progression

Dong,Ruofan; Qiu,Haifeng; Du,Guiqiang; Wang,Yuan; Yu,Jinjin; Mao,Caiping

doi:10.3892/mmr.2014.2622

Restoration of microRNA‑218 increases cellular chemosensitivity to cervical cancer by inhibiting cell‑cycle progression

Authors:
- Ruofan Dong
- Haifeng Qiu
- Guiqiang Du
- Yuan Wang
- Jinjin Yu
- Caiping Mao
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, P.R. China, Department of Obstetrics and Gynecology, International Peace Maternity and Child Health Hospital of the China Welfare Institute Affiliated to Shanghai Jiaotong University, Shanghai 200030, P.R. China, Department of Obstetrics and Gynecology, Shanghai First People's Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 200080, P.R. China, Department of Obstetrics and Gynecology, The Affiliated Hospital of Jiangnan University and the Fourth People's Hospital of Wuxi, Wuxi, Jiangsu 214062, P.R. China
Published online on: October 10, 2014 https://doi.org/10.3892/mmr.2014.2622
Pages: 3289-3295

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

We previously reported frequent loss of microRNA‑218 (miR‑218) in human cervical cancer, which was associated with tumor progression and poor prognosis. In this study, we investigated whether restoration of the miR‑218 level is a valid strategy for the treatment of cervical cancer. The expression of miR‑218 in cervical cancer samples and cell lines was quantified by reverse transcription TaqMan quantitative (RT‑q)PCR. Overexpression of miR‑218 was achieved by both transient and stable transfection, using a miR‑218 mimic and a miR‑218‑expressing plasmid, respectively. Alterations in cellular proliferation and cell‑cycle progression were measured by the MTT assay and flow cytometry analysis. Nude mice bearing SiHa xenografts were used to investigate the functions of miR‑218 and carboplatin on tumor growth and weight. The expression of cycle‑related proteins was detected by western blotting and immunohistochemical staining. In vitro, miR‑218 significantly inhibited cellular growth in all four cell lines tested (P=0.021 for CaSki, P=0.009 for HeLa, P=0.016 for SiHa, and P=0.029 for C33A). Overexpression of miR‑218 induced G1 phase arrest and reduced expression of cyclin D1 and CDK4. In vivo, restoration of miR‑218 notably inhibited tumor growth and decreased tumor weight. In primary cultured samples, tumors with high levels of miR‑218 were more sensitive to carboplatin (R2=0.3319, P=0.0026); consistently, miR‑218 overexpression suppressed tumor growth, induced cell‑cycle arrest, and reduced the cyclin D1 level. Based on these and previous results, we conclude that restoration of the miR‑218 level inhibits the growth of cervical cancer cells both in vitro and in vivo; furthermore, overexpression of miR‑218 sensitizes cervical cancer cells to carboplatin. Our findings suggest a novel therapy for cervical cancer based on miR‑218, especially in patients with reduced levels of miR‑218.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar
2	American Cancer Society. Cancer Facts & Figures 2011. American Cancer Society; Atlanta: 2011
3	Davis-Dusenbery BN and Hata A: microRNA in cancer: the involvement of aberrant microRNA biogenesis regulatory pathways. Genes Cancer. 1:1100–1114. 2010. View Article : Google Scholar : PubMed/NCBI
4	Lee JW, Choi CH, Choi JJ, et al: Altered microRNA expression in cervical carcinomas. Clin Cancer Res. 14:2535–2542. 2008. View Article : Google Scholar : PubMed/NCBI
5	Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
6	He L and Hannon GJ: MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 5:522–531. 2004. View Article : Google Scholar : PubMed/NCBI
7	Kloosterman WP and Plasterk RH: The diverse functions of microRNAs in animal development and disease. Dev Cell. 11:441–450. 2006. View Article : Google Scholar : PubMed/NCBI
8	Lu J, Getz G, Miska EA, et al: MicroRNA expression profiles classify human cancers. Nature. 435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
9	Uesugi A, Kozaki K, Tsuruta T, et al: The tumor suppressive microRNA miR-218 targets the mTOR component Rictor and inhibits AKT phosphorylation in oral cancer. Cancer Res. 71:5765–5778. 2011. View Article : Google Scholar : PubMed/NCBI
10	Zhang B, Pan X, Cobb GP and Anderson TA: microRNAs as oncogenes and tumor suppressors. Dev Biol. 302:1–12. 2007. View Article : Google Scholar : PubMed/NCBI
11	Tatarano S, Chiyomaru T, Kawakami K, et al: miR-218 on the genomic loss region of chromosome 4p15.31 functions as a tumor suppressor in bladder cancer. Int J Oncol. 39:13–21. 2011.PubMed/NCBI
12	Wu DW, Cheng YW, Wang J, Chen CY and Lee H: Paxillin predicts survival and relapse in non-small cell lung cancer by microRNA-218 targeting. Cancer Res. 70:10392–10401. 2010. View Article : Google Scholar : PubMed/NCBI
13	Song L, Huang Q, Chen K, et al: miR-218 inhibits the invasive ability of glioma cells by direct downregulation of IKK-β. Biochem Biophys Res Commun. 402:135–140. 2010.PubMed/NCBI
14	Alajez NM, Lenarduzzi M, Ito E, et al: MiR-218 suppresses nasopharyngeal cancer progression through downregulation of survivin and the SLIT2-ROBO1 pathway. Cancer Res. 71:2381–2391. 2011. View Article : Google Scholar
15	Tie J, Pan Y, Zhao L, et al: MiR-218 inhibits invasion and metastasis of gastric cancer by targeting the Robo1 receptor. PLoS Genet. 6:e10008792010. View Article : Google Scholar : PubMed/NCBI
16	Yu J, Wang Y, Dong R, Huang X, Ding S and Qiu H: Circulating microRNA-218 was reduced in cervical cancer and correlated with tumor invasion. J Cancer Res Clin Oncol. 138:671–674. 2012. View Article : Google Scholar
17	Schmittgen TD and Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
18	Lu D, Wu Y, Wang Y, et al: CREPT accelerates tumorigenesis by regulating the transcription of cell-cycle-related genes. Cancer Cell. 21:92–104. 2012. View Article : Google Scholar : PubMed/NCBI
19	Cancer Research UK. Cervical cancer survival statistics. Let’s Beat Cancer Sooner. http://info.cancerresearchuk.org/cancerstats/types/cervix/survival/. Accessed, April 2011
20	Nana-Sinkam SP and Croce CM: Clinical applications for microRNAs in cancer. Clin Pharmacol Ther. 93:98–104. 2013. View Article : Google Scholar
21	Janssen HL, Reesink HW, Lawitz EJ, et al: Treatment of HCV infection by targeting microRNA. N Engl J Med. 368:1685–1694. 2013. View Article : Google Scholar : PubMed/NCBI
22	Wang R, Ma J, Wu Q, et al: Functional role of miR-34 family in human cancer. Curr Drug Targets. 14:1185–1191. 2013. View Article : Google Scholar : PubMed/NCBI
23	Fish JE, Wythe JD, Xiao T, et al: A Slit/miR-218/Robo regulatory loop is required during heart tube formation in zebrafish. Development. 138:1409–1419. 2011. View Article : Google Scholar : PubMed/NCBI
24	Gao C, Zhang Z, Liu W, Xiao S, Gu W and Lu H: Reduced microRNA-218 expression is associated with high nuclear factor kappa B activation in gastric cancer. Cancer. 116:41–49. 2009.PubMed/NCBI
25	Leath CA III and Straughn JM Jr: Chemotherapy for advanced and recurrent cervical carcinoma: results from cooperative group trials. Gynecol Oncol. 129:251–257. 2013. View Article : Google Scholar : PubMed/NCBI
26	Scatchard K, Forrest JL, Flubacher M, Cornes P and Williams C: Chemotherapy for metastatic and recurrent cervical cancer. Cochrane Database Syst Rev. 10:CD0064692012.PubMed/NCBI
27	He X, Dong Y, Wu CW, et al: MicroRNA-218 inhibits cell cycle progression and promotes apoptosis in colon cancer by downregulating BMI1 polycomb ring finger oncogene. Mol Med. 18:1491–1498. 2012.PubMed/NCBI
28	Ziliak D, Gamazon ER, Lacroix B, Kyung Im H, Wen Y and Huang RS: Genetic variation that predicts platinum sensitivity reveals the role of miR-193b^* in chemotherapeutic susceptibility. Mol Cancer Ther. 11:2054–2061. 2012. View Article : Google Scholar : PubMed/NCBI
29	Wei J, Gao W, Zhu CJ, et al: Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non-small cell lung cancer. Chin J Cancer. 30:407–414. 2011. View Article : Google Scholar : PubMed/NCBI